A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis
Abstract Background Systemic Sclerosis is a multifactorial autoimmune rheumatic disease characterized by inflammation, fibrosis, immune dysregulation and vascular dysfunction. Methods An open label, prospective, non-comparative study evaluating ambrisentan with an antifibrotic agent in diffuse cutan...
Main Authors: | Annemarie Schorpion, Max Shenin, Robin Neubauer, Chris T. Derk |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-05-01
|
Series: | BMC Rheumatology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s41927-018-0021-z |
Similar Items
-
Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation—a prospective, observational study
by: Kristofer Andréasson, et al.
Published: (2020-10-01) -
A randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of Eisenmenger syndrome
by: Shaadab Mohammed, et al.
Published: (2021-09-01) -
Systemic sclerosis – diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2: treatment
by: Dorota Krasowska, et al.
Published: (2017-12-01) -
Treatment of systemic sclerosis associated fibrotic manifestations: Current options and future directions
by: Dimitrios Daoussis, et al.
Published: (2019-01-01) -
Ambrisentan-induced severe asymptomatic thrombocytopenia
by: Dana Kigitovica, et al.
Published: (2020-10-01)